Koy A, Weinsheimer M, Pauls K A M, Kühn A A, Krause P, Huebl J, Schneider G-H, Deuschl G, Erasmi R, Falk D, Krauss J K, Lütjens G, Schnitzler A, Wojtecki L, Vesper J, Korinthenberg R, Coenen V A, Visser-Vandewalle V, Hellmich M, Timmermann L
Department of Neurology, University Hospital of Cologne, Germany; Department of Paediatrics, University Hospital of Cologne, Germany.
Department of Neurology, University Hospital of Cologne, Germany.
Eur J Paediatr Neurol. 2017 Jan;21(1):136-146. doi: 10.1016/j.ejpn.2016.05.023. Epub 2016 Jun 25.
Data on paediatric deep brain stimulation (DBS) is limited, especially for long-term outcomes, because of small numbers in single center series and lack of systematic multi-center trials.
We seek to systematically evaluate the clinical outcome of paediatric patients undergoing DBS.
A German registry on paediatric DBS (GEPESTIM) was created to collect data of patients with dystonia undergoing DBS up to the age of 18 years. Patients were divided into three groups according to etiology (group 1 inherited, group 2 acquired, and group 3 idiopathic dystonia).
Data of 44 patients with a mean age of 12.8 years at time of operation provided by 6 German centers could be documented in the registry so far (group 1 n = 18, group 2 n = 16, group 3 n = 10). Average absolute improvement after implantation was 15.5 ± 18.0 for 27 patients with pre- and postoperative Burke-Fahn-Marsden Dystonia Rating scale movement scores available (p < 0.001) (group 1: 19.6 ± 19.7, n = 12; group 2: 7.0 ± 8.9, n = 8; group 3: 19.2 ± 20.7, n = 7). Infection was the main reason for hardware removal (n = 6). 20 IPG replacements due to battery expiry were necessary in 15 patients at 3.7 ± 1.8 years after last implantation.
Pre- and postoperative data on paediatric DBS are very heterogeneous and incomplete but corroborate the positive effects of DBS on inherited and acquired dystonia. Adverse events including relatively frequent IPG replacements due to battery expiry seem to be a prominent feature of children with dystonia undergoing DBS. The registry enables collaborative research on DBS treatment in the paediatric population and to create standardized management algorithms in the future.
由于单中心研究病例数量少且缺乏系统性多中心试验,小儿深部脑刺激(DBS)的数据有限,尤其是关于长期疗效的数据。
我们旨在系统评估接受DBS治疗的儿科患者的临床结局。
建立了一个德国儿科DBS登记系统(GEPESTIM),以收集18岁以下接受DBS治疗的肌张力障碍患者的数据。根据病因将患者分为三组(第1组为遗传性,第2组为后天性,第3组为特发性肌张力障碍)。
到目前为止,德国6个中心提供的44例手术时平均年龄为12.8岁的患者数据已记录在该登记系统中(第1组n = 18,第2组n = 16,第3组n = 10)。27例有术前和术后伯克 - 法恩 - 马斯登肌张力障碍评定量表运动评分的患者,植入后平均绝对改善为15.5±18.0(p < 0.001)(第1组:19.6±19.7,n = 12;第2组:7.0±8.9,n = 8;第3组:19.2±20.7,n = 7)。感染是硬件移除的主要原因(n = 6)。15例患者在最后一次植入后3.7±1.8年因电池耗尽需要进行20次植入式脉冲发生器(IPG)更换。
小儿DBS的术前和术后数据非常异质且不完整,但证实了DBS对遗传性和后天性肌张力障碍的积极作用。不良事件包括因电池耗尽导致相对频繁的IPG更换,这似乎是接受DBS治疗的肌张力障碍儿童的一个突出特征。该登记系统有助于开展儿科人群DBS治疗的合作研究,并在未来创建标准化的管理算法。